Wang J, Jiang S, Hu A, Zhou A, Hu T, Li H
Heliyon. 2024; 10(5):e27325.
PMID: 38449611
PMC: 10915413.
DOI: 10.1016/j.heliyon.2024.e27325.
Song B, Choi S, Goh M, Kang W, Sinn D, Gwak G
JHEP Rep. 2023; 5(9):100810.
PMID: 37538246
PMC: 10393797.
DOI: 10.1016/j.jhepr.2023.100810.
Liu L, Wang C, Deng S, Yuan T, Zhu X, Deng Y
Sci Rep. 2023; 13(1):9690.
PMID: 37322025
PMC: 10272131.
DOI: 10.1038/s41598-023-35733-0.
Chan W, Chong S, Chang F, Lai L, Chuah K, Mustapha N
Hepatol Int. 2023; 17(4):870-881.
PMID: 37237087
PMC: 10218774.
DOI: 10.1007/s12072-023-10550-9.
Fan H, Zhang P, Liu Z, Zhao R, Suo C, Chen X
J Clin Transl Hepatol. 2023; 11(3):525-533.
PMID: 36969883
PMC: 10037522.
DOI: 10.14218/JCTH.2022.00214.
Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study.
Xin Z, Huang J, Cao Q, Wang J, He R, Hou T
Nutr Metab (Lond). 2023; 20(1):15.
PMID: 36899397
PMC: 10007748.
DOI: 10.1186/s12986-023-00734-3.
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis.
Jacobson I, Wong V, Castera L, Anstee Q, Noureddin M, Cusi K
J Clin Gastroenterol. 2022; 57(3):253-264.
PMID: 36251413
PMC: 9911115.
DOI: 10.1097/MCG.0000000000001780.
Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4.
Shanahan W, Bagwe I, Brassill M, ORegan P
Ir J Med Sci. 2022; 192(2):649-654.
PMID: 35486350
DOI: 10.1007/s11845-022-03019-5.
Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.
Lee H, Lee H, Kim S, Kim H
Clin Transl Gastroenterol. 2022; 13(1):e00435.
PMID: 35080508
PMC: 8806363.
DOI: 10.14309/ctg.0000000000000435.
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
Chan W, Tan S, Chan S, Lee Y, Tee H, Mahadeva S
J Gastroenterol Hepatol. 2022; 37(5):795-811.
PMID: 35080048
PMC: 9303255.
DOI: 10.1111/jgh.15787.
Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.
Lin H, Zhang X, Li G, Wong G, Wong V
J Clin Transl Hepatol. 2021; 9(6):972-982.
PMID: 34966660
PMC: 8666360.
DOI: 10.14218/JCTH.2021.00201.
MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y
Diabetes Metab Syndr Obes. 2021; 14:3417-3425.
PMID: 34349535
PMC: 8326380.
DOI: 10.2147/DMSO.S316096.
Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Mendez-Sanchez N, Diaz-Orozco L
Med Sci Monit. 2021; 27:e933860.
PMID: 34248137
PMC: 8284081.
DOI: 10.12659/MSM.933860.
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.
Arrese M, Arab J, Barrera F, Kaufmann B, Valenti L, Feldstein A
Semin Liver Dis. 2021; 41(4):421-434.
PMID: 34233370
PMC: 8492194.
DOI: 10.1055/s-0041-1730927.
NAFLD and HCC: Time to Bridge the Gap.
Cholankeril G, Kanwal F
Hepatology. 2021; 74(5):2336-2338.
PMID: 34164841
PMC: 9277557.
DOI: 10.1002/hep.32025.
Prevalence of Fatty Liver Disease is Driven by Prediabetes and Diabetes: US NHANES 2017-2018.
Claypool K, Patel C
Clin Gastroenterol Hepatol. 2021; 20(3):712-713.
PMID: 33965575
PMC: 10291529.
DOI: 10.1016/j.cgh.2021.05.003.
